Clorox (CLX) reported a mixed fiscal year 2025 driven by strong margin recovery and cost actions but limited top-line growth. Net sales were essentially flat at $7,104 versus $7,093 a year earlier as ERP-transition shipments, divestitures and a softer second half offset a strong first half. Gross margin expanded by 220 basis points to 45.2, largely from cost savings, higher volume and benefits from divestitures. Reported earnings before income taxes rose to $1,078 and diluted EPS increased to $6.52, up 190 from the prior year. Economic Profit increased to $756. Operating cash flow improved to $981 and free cash flow was $761 (~10.7 of net sales). The company completed the divestiture of the Better Health VMS business, announced a 2 dividend increase in July 2025, and noted ongoing impacts from the August 2023 cyberattack and the ERP transition.
Christopher J. Williams, a director of Clorox Co. (CLX), reported two grants of Deferred Stock Units (DSUs) on a Form 4. On 08/29/2025 he received 199.8083 DSUs through dividend reinvestment; on 09/30/2025 he received 212.8954 DSUs in lieu of quarterly director fees. The DSUs are 1-for-1 and will be settled in Clorox common stock upon the reporting person’s retirement or other termination of director service. Following these transactions, the reporting person beneficially owns 19,458.9483 shares (reported as 19,246.0529 before the 09/30/2025 grant).
Russell J. Weiner, a director of Clorox Co. (CLX), received additional deferred stock units (DSUs) under the company's Independent Directors' Deferred Compensation Plan. On 08/29/2025 he was credited with 156.7731 DSUs via dividend reinvestment and on 09/30/2025 he received 253.4469 DSUs in lieu of quarterly director fees. The reported DSUs will be settled 100% in Clorox common stock when the reporting person retires or otherwise terminates service as a director. After these transactions the reporting person beneficially owned 15,354.2406 DSUs (expressed as common stock equivalents) held directly.
Matthew J. Shattock, a director of Clorox Co. (CLX), reported two grants of Deferred Stock Units (DSUs) that increase his notional holdings. On 08/29/2025 he received 172.9087 DSUs through dividend reinvestment, and on 09/30/2025 he received 415.6529 DSUs in lieu of quarterly director fees.
The report shows DSUs convert on a 1-for-1 basis into common stock at the director's retirement or termination and that the total DSUs after the September grant equal 17,070.6618 shares. Both grants are reported as direct beneficial ownership and have a $0.00 per-unit price because they are deferred compensation awards.
Clorox director Stephanie Plaines reported two grants of Deferred Stock Units (DSUs) that increase her beneficial ownership. On 08/29/2025 she received 53.9884 DSUs through dividend reinvestment, and on 09/30/2025 she received 212.8954 DSUs in lieu of quarterly director fees. The filing shows the DSUs will be settled 100% in Clorox common stock upon the reporting person’s retirement or other termination, and total reported beneficial ownership after the transactions is 5,413.1984 shares (previously 5,200.303).
Spencer C. Fleischer, a director of Clorox Co. (CLX), reported two acquisitions of deferred stock units under the board’s deferred compensation plan. On 08/29/2025 he received 192.9623 deferred stock units through dividend reinvestment and on 09/30/2025 he received 212.8954 units in lieu of quarterly director fees. The filing states the deferred stock units will be settled 1-for-1 in Clorox common stock upon the reporting person’s retirement or termination. Following the reported transactions, the filing shows total beneficial ownership of 18,799.5242 common shares.
Pierre R. Breber, a Director of Clorox Co. (CLX), reported transactions showing continued ownership and receipt of deferred compensation units. The filing shows indirect ownership of 9,000 shares through a family trust. On 08/29/2025 he acquired 502.2399 deferred stock units via dividend reinvestment under the Independent Directors' Deferred Compensation Plan, and on 09/30/2025 he received 263.5848 deferred stock units in lieu of quarterly director fees. The report states the deferred stock units are 1-for-1 and "will be settled 100% in Clorox stock" upon the reporting person's retirement or other termination of service as a Director. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Laurene E. Peck, Vice President, Chief Accounting Officer & Corporate Controller of Clorox Co. (CLX), reported an acquisition on 09/16/2025 of 1,441 shares of common stock via restricted stock units at an attributable price of $124.85 per share. After the transaction Ms. Peck beneficially owned 5,821 shares directly and 100 shares indirectly through a trust of a parent. The restricted stock units vest in four equal installments on October 5 of 2026, 2027, 2028 and 2029. The Form 4 was signed by an attorney-in-fact on 09/18/2025.
Stacey Grier, EVP & Executive Chief of Staff at The Clorox Company (CLX), reported an acquisition of 3,364 restricted stock units on 09/16/2025. The Form 4 shows the units were recorded at a price of $124.85 and, after the transaction, Ms. Grier beneficially owned 23,190 shares. The restricted stock units vest in four equal installments, with one-quarter vesting on each of October 5, 2026, 2027, 2028 and 2029. The filing was signed by an attorney-in-fact on 09/18/2025.
Angela C. Hilt, Executive Vice President and Chief Legal Officer of The Clorox Company (CLX), reported an acquisition of 7,048 shares of Clorox common stock on 09/16/2025 at a reported price of $124.85 per share. After the reported transaction she beneficially owns 26,881 shares directly. The filing also discloses indirect ownership of 609.663 shares held via the company 401(k) plan. The acquired shares are described as Restricted Stock Units that will vest in four equal installments on October 5 of 2026, 2027, 2028 and 2029.